Know Cancer

or
forgot password

PHASE II STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE PLUS RECOMBINANT HUMAN GRANULOCYTE-COLONY STIMULATING FACTOR (rhG-CSF) IN THE TREATMENT OF FOLLICULAR LOW-GRADE NON-HODGKIN'S LYMPHOMA


Phase 2
18 Years
55 Years
Not Enrolling
Both
Lymphoma

Thank you

Trial Information

PHASE II STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE PLUS RECOMBINANT HUMAN GRANULOCYTE-COLONY STIMULATING FACTOR (rhG-CSF) IN THE TREATMENT OF FOLLICULAR LOW-GRADE NON-HODGKIN'S LYMPHOMA


OBJECTIVES: I. Determine the feasibility of high-dose cyclophosphamide and filgrastim
(G-CSF) in patients with stage IV, relapsed, or progressive low-grade follicular
non-Hodgkin's lymphoma. II. Determine the toxic effects of this regimen in these patients,
including those with marrow involvement. III. Determine the rates of complete remission (CR)
and partial remission and time to failure in previously treated and untreated patients. IV.
Determine the effectiveness of this regimen in eradicating bcl-2 rearrangements, as
determined by polymerase chain reaction (PCR), in previously untreated patients. V.
Correlate the duration of CR to PCR results in responding patients.

OUTLINE: Patients are stratified according to prior treatment (yes vs no). Patients receive
cyclophosphamide IV over 90 minutes on day 1 and filgrastim (G-CSF) subcutaneously beginning
on day 3 and continuing until blood counts recover. Treatment continues every 2 weeks for 4
courses in the absence of disease progression or stable disease. Patients who achieve
complete remission (CR) after completion of course 4 receive 2 additional courses. Patients
who achieve partial remission (PR) after completion of course 4 receive 2 additional
courses, and those who achieve CR after completion of course 6 receive 2 additional courses.
Patients are followed every 2 months for 6 months, every 6 months for 2 years, and then
annually thereafter.

PROJECTED ACCRUAL: A total of 60 patients (30 per stratum) will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS: Histologically proven low-grade non-Hodgkin's lymphoma of the
following subtypes: Follicular, predominantly small cleaved cell Follicular mixed (small
cleaved and large cell) Previously treated on Protocol CLB 8691 or previously untreated
Previously untreated patients with Stage IV disease (Ann Arbor classification) must meet
the following conditions: Documented bone marrow involvement Lymph node biopsy must not
show higher grade lymphoma At least 1 additional risk factor as follows: At least 2
extranodal sites Nodes or nodal group at least 5 cm Male Previously treated patients must
have progressed or relapsed on Protocol CLB-8691 Recurrence should be documented by biopsy
if possible Bidimensionally measurable disease by physical exam, radiograph, CT, or MRI
(sonography and barium studies alone not acceptable) Measurable liver disease defined as:
Mass greater than 3.5 cm on CT, MRI, or ultrasound OR Histologically documented
lymphomatous hepatomegaly more than 5 cm below the costal margin The following disease
manifestations are not considered measurable: Ascites or pleural effusion Bony disease
(lytic lesions on x-ray should be documented and followed) CNS lesions Bone marrow
involvement No lymphomatous involvement (including CNS lymphoma) requiring immediate
radiotherapy A new classification scheme for adult non-Hodgkin's lymphoma has been adopted
by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former
terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol
uses the former terminology.

PATIENT CHARACTERISTICS: Age: 18 to physiologic 55 Patients over 55 are eligible only if
study chairperson agrees that the patient can tolerate intensive chemotherapy Performance
status: Zubrod 0-1 Life expectancy: More than 2 years Hematopoietic: Granulocyte count at
least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9.0 g/dL Hepatic:
Bilirubin less than 1.5 times normal Renal: Creatinine less than 1.5 times normal
Cardiovascular: LVEF at least 50% No acute changes or arrhythmias on ECG No cardiomegaly
on chest x-ray or physical exam No uncontrolled or severe cardiovascular disease,
including myocardial infarction within the past 6 months or congestive heart failure (CHF)
No active cardiac problems, including compensated CHF or angina Other: HIV negative No
other malignancy within the past 5 years except curatively treated basal cell skin cancer
or carcinoma in situ of the cervix No active uncontrolled bacterial, viral, or fungal
infection No other serious medical illness that would limit survival to less than 2 years
No psychiatric condition that would preclude informed consent or compliance No
uncontrolled duodenal ulcer Not pregnant Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: Prior interferon only on Protocol CLB-8691
allowed Chemotherapy: Prior oral cyclophosphamide only on Protocol CLB-8691 allowed No
concurrent chemotherapy Endocrine therapy: No chronic steroids for other health problems
No concurrent steroids for any condition including documented CNS metastases, adrenal
failure, or septic shock Nonsteroidal hormonal drugs for nondisease related problems
allowed (e.g., insulin for diabetes) Radiotherapy: See Disease Characteristics No prior
radiotherapy No concurrent palliative radiotherapy Surgery: At least 2 weeks since prior
major surgery Other: No other prior therapy

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Primary Purpose: Treatment

Outcome Measure:

Toxicity

Outcome Time Frame:

12 weeks

Safety Issue:

Yes

Principal Investigator

Robert T. Perri, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Veterans Affairs Medical Center - Minneapolis

Authority:

United States: Federal Government

Study ID:

CDR0000077861

NCT ID:

NCT00002501

Start Date:

October 1992

Completion Date:

January 2006

Related Keywords:

  • Lymphoma
  • stage IV grade 1 follicular lymphoma
  • stage IV grade 2 follicular lymphoma
  • recurrent grade 1 follicular lymphoma
  • recurrent grade 2 follicular lymphoma
  • Lymphoma
  • Lymphoma, Follicular
  • Lymphoma, Non-Hodgkin

Name

Location

University of Chicago Cancer Research CenterChicago, Illinois  60637
University of Iowa Hospitals and ClinicsIowa City, Iowa  52242
University of Massachusetts Memorial Medical CenterWorcester, Massachusetts  01655
Comprehensive Cancer Center of Wake Forest University Baptist Medical CenterWinston-Salem, North Carolina  27157-1082
Rhode Island HospitalProvidence, Rhode Island  02903
CCOP - Southern Nevada Cancer Research FoundationLas Vegas, Nevada  89106
Marlene & Stewart Greenebaum Cancer Center, University of MarylandBaltimore, Maryland  21201
Ellis Fischel Cancer Center - ColumbiaColumbia, Missouri  65203
Barnes-Jewish HospitalSaint Louis, Missouri  63110
Norris Cotton Cancer CenterLebanon, New Hampshire  03756
CCOP - North Shore University HospitalManhasset, New York  11030
State University of New York - Upstate Medical UniversitySyracuse, New York  13210
CCOP - Southeast Cancer Control ConsortiumWinston-Salem, North Carolina  27104-4241
University of Tennessee, Memphis Cancer CenterMemphis, Tennessee  38103
Mount Sinai Medical Center, NYNew York, New York  10029